Mostrando 4 resultados de: 4
Subtipo de publicación
Article(4)
Área temáticas
Enfermedades(2)
Farmacología y terapéutica(2)
Bioquímica(1)
Fisiología humana(1)
Química analítica(1)
Área de conocimiento
Cáncer(2)
Descubrimiento de fármacos(2)
Bioquímica(1)
Farmacología(1)
Química analítica(1)
Origen
scopus(4)
Development and validation of a novel LC–MS/MS method for simultaneous determination of abiraterone and its seven steroidal metabolites in human serum: Innovation in separation of diastereoisomers without use of a chiral column
ArticleAbstract: Abiraterone acetate (AA), the prodrug of abiraterone, is FDA-approved for the treatment of castratioPalabras claves:abiraterone, LC–MS/MS, Metabolites, Method validation, Prostate cancerAutores:Alyamani M., Anderson D., Li Z., Richard J. Auchus, Sharifi N., Upadhyay S.K.Fuentes:scopusConversion of abiraterone to D4A drives anti-tumour activity in prostate cancer
ArticleAbstract: Prostate cancer resistance to castration occurs because tumours acquire the metabolic capability ofPalabras claves:Autores:Alyamani M., Bishop A., Bunch D., Dreicer R., Garcia J., Li Z., Liu J., Richard J. Auchus, Sharifi N., Upadhyay S.K.Fuentes:scopusRedirecting abiraterone metabolism to fine-tune prostate cancer anti-androgen therapy
ArticleAbstract: Abiraterone blocks androgen synthesis and prolongs survival in patients with castration-resistant prPalabras claves:Autores:Abazeed M., Alyamani M., Balk S., Li J., Li Z., Richard J. Auchus, Rogacki K., Sharifi N., Taplin M., Upadhyay S.K.Fuentes:scopusSteroidogenic Metabolism of Galeterone Reveals a Diversity of Biochemical Activities
ArticleAbstract: Galeterone is a steroidal CYP17A1 inhibitor, androgen receptor (AR) antagonist, and AR degrader, undPalabras claves:3βHSD, abiraterone, Androgens, CYP17A1, galeterone, metabolism, Prostate cancer, steroidsAutores:Alyamani M., Berk M.P., Li J., Li Z., Richard J. Auchus, Sharifi N., Tang J., Upadhyay S.K.Fuentes:scopus